Short answer
Viatris (VTRS) filed an 8-K current report with the SEC on October 8, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer.
Viatris 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer
- Offer requires more than 50% of Pacira shares tendered, with no financing condition
- Pacira becomes a wholly owned Viatris subsidiary after the merger, without a stockholder vote under DGCL Section 251(h)
- Offer closing depends on HSR antitrust clearance and other customary conditions
- Outside closing date April 8, 2027, extendable to July 8, 2027; Pacira termination fee $62 million under specified circumstances
Item 8.01 · Other Events
- Viatris and Pacira announced a merger agreement on October 8, 2026, initiating a proposed acquisition subject to closing conditions
- Tender offer has not commenced, with Viatris expected to file Schedule TO and Pacira Schedule 14D-9
- Completion requires at least a majority of Pacira shares outstanding after the offer expires to be validly tendered and not withdrawn
- Key risks include regulatory approval, competing offers, integration execution, and realization of expected synergies
- Investor presentation and transaction details are available in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing equity at $1.65 billion
- Pacira generated $746 million revenue and $177 million adjusted EBITDA for the twelve months ended June 30, 2026
- EXPAREL and ZILRETTA add patent-protected, high-margin non-opioid pain products to Viatris’ innovative medicines portfolio
- Funding primarily from excess cash, with short-term borrowings, expected minimal gross-leverage impact
- Closing targeted by end-2026, subject to majority tender and regulatory clearance; immediately accretive guidance impact expected
Item EX-99.2 · Exhibit EX-99.2
- Viatris plans to acquire Pacira BioSciences, signaling expansion into specialty pharmaceuticals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Viatris 8-K filings
Get the next VTRS 8-K as it lands
Follow VTRS for push alerts, or ask the research agent what this filing means.